- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S1786||Verteporfin||<1 mg/mL||100 mg/mL||<1 mg/mL|
|S8334||XMU-MP-1||<1 mg/mL||83 mg/mL||<1 mg/mL|
|S8554||Super-TDU||100 mg/mL||-1 mg/mL||-1 mg/mL|
|S8164||YAP-TEAD Inhibitor 1 (Peptide 17)||100 mg/mL||-1 mg/mL||-1 mg/mL|
|S8661||CA3(CIL56)||<1 mg/mL||97 mg/mL||<1 mg/mL|
- Hippo pathway Inhibitors (5)
- New Hippo pathway Products
|Catalog No.||Information||Product Use Citations||Product Validations|
Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.
Verteporfin treatment inhibits proliferation and induces apoptosis of Tsc1-null cells in vivo. Mice were administered i.p. with vehicle or verteporfin at a dose of 100 mg/kg every other day for 10 d before sacrifice. Mice were sacrificed at 6 wk of age. Three independent experiments were performed and mice in different treatments were pooled for analysis. Percentage of Ki67 and αSMA double-positive cells in α-SMA+ mesenchymal lesions in the indicated kidneys. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse.
XMU-MP-1 is an inhibitor of MST1/2 with IC50 values of 71.1±12.9 nM and 38.1±6.9 nM against MST1 and MST2, respectively.
Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.
Peptide 17 is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM.
CA3 has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties.